|1.||Kawakami, E: 2 articles (04/2001 - 10/2000)|
|2.||Hori, T: 2 articles (04/2001 - 10/2000)|
|3.||Shimizu, M: 2 articles (04/2001 - 10/2000)|
|4.||Maynard, L: 1 article (08/2008)|
|5.||Eun, H M: 1 article (08/2008)|
|6.||Albouy, M: 1 article (08/2008)|
|7.||Sanquer, A: 1 article (08/2008)|
|8.||Koizumi, Naoyuki: 1 article (02/2002)|
|9.||Minato, Kouichi: 1 article (02/2002)|
|10.||Iwamura, Satoshi: 1 article (02/2002)|
|1.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
08/01/1994 - "[Clinical study of TZP-4238 on patients with benign prostatic hypertrophy--with special reference to urodynamics]."
08/01/1994 - "[Study of clinical usefulness of an antiandrogen, TZP-4238, as a drug for treatment of benign prostatic hypertrophy--its influence on sexual function]."
04/01/2001 - "The effects of osaterone acetate (OSA), which is an anti-androgen agent being developed as a therapeutic drug for benign prostatic hypertrophy (BPH) in dogs, on the degree of prostatic regression and semen qualities were investigated. "
10/01/2000 - "It was shown that administration of osaterone acetate at 0.2 mg/kg or higher, sharply regressed prostatic hypertrophy during the early stage. "
10/01/2000 - "To dogs with prostatic hypertrophy, 0.1-1.0 mg/kg of osaterone acetate was orally administered for one week, and the regression rate was observed. "
08/01/1992 - "TZP-4238 (Group 3) produced marked atrophy of the prostate. "
03/01/1992 - "In contrast, TZP-4238 (Group 2) or CMA (Group 3) produced marked atrophy of the glandular epithelium. "
12/01/1990 - "In contrast, combined treatment with TZP-4238 (Group 3) or CMA (Group 4) produced marked atrophy of the glandular epithelium. "
08/01/1992 - "Therefore, it is suggested that TZP-4238 causes atrophy of the prostate without any significant histopathological changes in the adrenal glands or anterior pituitary ACTH cells under the present experimental conditions. "
08/01/1993 - "In contrast, combined treatment with TZP-4238 (Group 3) or CMA (Group 4) produced marked atrophy of the glandular epithelium, and the number of BrdU-positive cells were remarkably decreased compared with Group 2. In addition, the localization of glutathione-peroxidase (GSH-PO) which effectively reduces the lipid peroxides in the glandular epithelial cells was markedly decreased. "
|3.||Prostatic Neoplasms (Prostate Cancer)
08/01/1993 - "The inhibitory effect of TZP-4238 on the growth of R3327 tumor indicated the application of the compound to human prostatic cancer."
12/01/1995 - "The effects of the new steroidal antiandrogen, TZP-4238 on spontaneously-developed canine prostatic hyperplasia (BPH) were studied in comparison with those of chlormadinone acetate (CMA), a steroidal antiandrogen used for the treatment of BPH and prostatic cancer in Japan. "
08/01/1994 - "These results suggest that TZP-4238 exerts an antiandrogenic effect on the prostate without any compensatory change in the serum concentration of luteinizing hormone or testosterone in rats, and it is a useful drug for the treatment of androgen-dependent diseases such as prostatic hypertrophy and prostatic cancer."
|1.||Chlormadinone Acetate (Chlormadinone)
|4.||Androgen Receptors (Androgen Receptor)
|6.||Luteinizing Hormone (Lutropin)